Randomised trials of secondary prevention programmes in coronary heart disease: systematic review.
OBJECTIVE
To determine whether multidisciplinary disease management programmes for patients with coronary heart disease improve processes of care and reduce morbidity and mortality.


METHODS
Randomised clinical trials of disease management programmes in patients with coronary heart disease were identified by searching Medline 1966-2000, Embase 1980-99, CINAHL 1982-99, SIGLE 1980-99, the Cochrane controlled trial register, the Cochrane effective practice and organisation of care study register, and bibliographies of published studies.


METHODS
Studies were selected and data were extracted independently by two investigators, and summary risk ratios were calculated by using both the random effects model and the fixed effects model.


RESULTS
A total of 12 trials (9803 patients with coronary heart disease) were identified. Disease management programmes had positive impacts on processes of care. Patients randomised to these programmes were more likely to be prescribed efficacious drugs (risk ratio 2.14 (95% confidence interval 1.92 to 2.38) for lipid lowering drugs, 1.19 (1.07 to 1.32) for beta blockers, and 1.07 (1.03 to 1.11) for antiplatelet agents). Five out of seven trials evaluating risk factor profiles showed significantly greater improvements with these programmes in comparison with usual care (with effect sizes in the moderate range). Summary risk ratios were 0.91 (0.79 to 1.04) for all cause mortality, 0.94 (0.80 to 1.10) for recurrent myocardial infarction, and 0.84 (0.76 to 0.94) for admission to hospital. Five of the eight trials evaluating quality of life or functional status reported better outcomes in the intervention arms. Only three of these trials reported the costs of the intervention-the interventions were cost saving in two cases.


CONCLUSIONS
Disease management programmes improve processes of care, reduce admissions to hospital, and enhance quality of life or functional status in patients with coronary heart disease. The programmes' impact on survival and recurrent infarctions, their cost effectiveness, and the optimal mix of components remain uncertain.
McAlister
F A
FA
Division of General Internal Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada. Finlay.McAlister@ualberta.ca
Lawson
F M
FM
Teo
K K
KK
Armstrong
P W
PW
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D019468:Disease Management; D006760:Hospitalization; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012306:Risk; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors